These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 31515555)
21. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J J Clin Oncol; 2008 Apr; 26(12):2013-9. PubMed ID: 18421054 [TBL] [Abstract][Full Text] [Related]
22. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625 [TBL] [Abstract][Full Text] [Related]
23. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial. Matsui T; Nagata N; Hirata K; Okazaki S; Sato S; Nakamura M; Kim H; Oba K; Sakamoto J; Mishima H Anticancer Res; 2016 Jul; 36(7):3437-43. PubMed ID: 27354605 [TBL] [Abstract][Full Text] [Related]
24. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686 [TBL] [Abstract][Full Text] [Related]
25. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572 [TBL] [Abstract][Full Text] [Related]
26. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766 [TBL] [Abstract][Full Text] [Related]
27. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Vamvakas L; Matikas A; Karampeazis A; Hatzidaki D; Kakolyris S; Christophylakis C; Boukovinas I; Polyzos A; Georgoulias V; Souglakos J BMC Cancer; 2014 Apr; 14():277. PubMed ID: 24755296 [TBL] [Abstract][Full Text] [Related]
28. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women. Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047 [TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110 [TBL] [Abstract][Full Text] [Related]
30. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864 [TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Ozcelik M; Odabas H; Ercelep O; Yuksel S; Mert AG; Aydin D; Surmeli H; Isik D; Isik S; Oyman A; Oven Ustaalioglu BB; Aliustaoglu M; Gumus M Clin Transl Oncol; 2016 Jun; 18(6):617-24. PubMed ID: 26459249 [TBL] [Abstract][Full Text] [Related]
32. Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. Goey KKH; Elias SG; Hinke A; van Oijen MGH; Punt CJA; Hegewisch-Becker S; Arnold D; Koopman M Br J Cancer; 2017 Dec; 117(12):1768-1776. PubMed ID: 29123255 [TBL] [Abstract][Full Text] [Related]
33. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156 [TBL] [Abstract][Full Text] [Related]
34. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. Derksen JWG; Kurk SA; Peeters PHM; Dorresteijn B; Jourdan M; van der Velden AMT; Nieboer P; de Jong RS; Honkoop AH; Punt CJA; Koopman M; May AM J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):919-928. PubMed ID: 32107889 [TBL] [Abstract][Full Text] [Related]
35. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). Maiello E; Di Maggio G; Cordio S; Cinieri S; Giuliani F; Pisconti S; Rinaldi A; Febbraro A; Latiano TP; Aieta M; Rossi A; Rizzi D; Di Maio M; Colucci G; Bordonaro R Clin Colorectal Cancer; 2020 Jun; 19(2):109-115. PubMed ID: 32089455 [TBL] [Abstract][Full Text] [Related]
36. Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. Pander J; van Huis-Tanja L; Böhringer S; van der Straaten T; Gelderblom H; Punt C; Guchelaar HJ PLoS One; 2015; 10(7):e0131091. PubMed ID: 26222057 [TBL] [Abstract][Full Text] [Related]
37. The impact of age on first-line systemic therapy in patients with metachronous metastases from colorectal cancer. Razenberg LG; van Erning FN; Pruijt HF; Ten Tije AJ; van Riel JM; Creemers GJ; Lemmens VE J Geriatr Oncol; 2017 Jan; 8(1):37-43. PubMed ID: 27659548 [TBL] [Abstract][Full Text] [Related]
38. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072 [TBL] [Abstract][Full Text] [Related]
40. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]